Seaport Therapeutics SPTX Software and Technology Licenses, Net

Software and Technology Licenses, Net at other companies

Lockheed MartinLMT

$6.93B-19.0%

CHE

ChemedCHE

$9.9M+22.2%

UL SolutionsULS

$93M-24.4%

Fidelity National Information ServicesFIS

$7.04B+50.0%

PopularBPOP

$193.97M+21.9%

HubbellHUBB

$9.7M+54.0%

Other financials

Income statement

See full

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Balance sheet

See full

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Cash flow

See full

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Valuation

See full

Market cap$972.65M—

Enterprise value$925.08M—

Returns & leverage

See full

Debt / equity-0×—

Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's software and technology licenses, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Seaport Therapeutics 's software and technology licenses, net?: Seaport Therapeutics (SPTX) reported software and technology licenses, net of $3.84M in Q1 2026.